Evolving drugs in gastroesophageal reflux disease: Pharmacologic treatment beyond proton pump inhibitors

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1541-1548

  Johnson, David A ^a   Levy Iii, Benjamin H ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

GABAB receptor agonists; Gastroesophageal reflux disease; GERD pharmacology; MGluR5 receptor antagonists; Potassium competitive acid blockade

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 8 (2,6 DIMETHYLBENZYLAMINO) N (2 HYDROXYETHYL) 2,3 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; 8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; ADX 10059; ARBACLOFEN PLACARBIL; AZD 3355; BACLOFEN; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DEXLANSOPRAZOLE; ESOMEPRAZOLE; GLUTAMATE RECEPTOR ANTAGONIST; HERBACEOUS AGENT; ITRIGLUMIDE; LESOGABERAN; LINAPRAZAN; MOSAPRIDE; OMEPRAZOLE; POTASSIUM COMPETITIVE ACID BLOCKER; PROTON PUMP INHIBITOR; RIKKUNSHITO; SEROTONIN 4 AGONIST; UNCLASSIFIED DRUG; XP 19986; Z 360;

ABDOMINAL PAIN; ADD ON THERAPY; CLINICAL TRIAL; CONSTIPATION; DELAYED DRUG RELEASE; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DYSURIA; ECCHYMOSIS; FATIGUE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HOT FLUSH; HUMAN; HYPESTHESIA; LOW DRUG DOSE; NAUSEA; NONHUMAN; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; REFLUX ESOPHAGITIS; REVIEW; SIDE EFFECT; SOMNOLENCE; SORE THROAT; TINNITUS; URINE VOLUME; VISUAL DISORDER; VOMITING; XEROSTOMIA;

GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; PROTON PUMP INHIBITORS;

EID: 77952696191     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.482932     Document Type: Review

References (37)

1. Poh C, Gasiorowska A, Fass R, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endoscop 2010;71(1):28-34
2. Boeckxstaens GE. Reflux inhibitors: a new approach for GERD?. Curr Opin Pharmacol 2008;8:1-5
3. Kaywood C, Wakefield M, Tack J, et al. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009;58:1192-1199
4. Boeckxstaens GE. Emerging drugs for gastroesophageal reflux disease. Exp Opin Emerg Drug 2009;14:481-491
5. Dent J. Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994;201:55-61 (Pubitemid 24165477)
6. Armstrong D. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther 2004;20(Suppl 5):19-26
7. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(Suppl 1):3-7
8. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999;159:649-657
9. Katz PO, Ginsberg GG, Hoyle PE, et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007;25:617-628
10. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007;5:1385-1391
11. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008;103:20-26
12. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation -- results from two randomized controlled studies. Aliment Pharmacol Ther 2009;29:731-741
13. Orlando RC. Esophageal damage and repair in GERD. J Clin Gastro 2007;41:S108-13
14. Bredenoord AJ. Lesogaberan, a GABAB agonist for the potential treatment of gastroesophageal reflux disease. IDrugs 2009;12:576-584
15. Smid S, Young R, Cooper N, Blackshaw L. GABAB expressed on vagal afferent neurons inhibit gastric mechanosensitivity in perret proximal stomach. Gastro Liver Physiol 2001;281:G1494-501
16. Lee KJ, Vos R, Janssens J, Tack J. Differential effects of baclofen on lower oesophageal sphincter pressure and proximal gastric motility in humans. Aliment Pharmacol Ther 2003;18:199-207
17. Van Herwaarden MA, Samson M, Rydholm H, Smout AJPM. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002;16:1655-1662
18. Aronoff GM, Gallagher RM, Patel JG. Pharmacological management of chronic pain: a review. In: Tollison JW, Satterhwaite JR, editors. Practical pain management. Lippincott, Williams & Wilkins, Philadelphia, PA; 2002. p. 253-278
19. Takeuchi K, Nishiwaki H, Niida H, et al. Body temperature-dependent action of baclofen in rat stomach. Relation to acid secretion and ulcerogenicity. Dig Dis Sci 1990;35:458-466
20. Piqueras L, Martinez V. Peripheral GABAB agonists stimulate gastric acid secretion in mice. Br J Pharmacol 2004;142:1038-1048
21. Lehmann A, Antonsson M, Holmberg A, et al. (R)-(3-Amino-2-fluoropropyl) Phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. J Pharmacol Exper Ther 2009;331:504-512
22. Lehmann A, Blackshaw LA, Elebring T, et al. The new reflux inhibitor AZD3355 has a low propensity for inducing central side effects due to its affinity for the GABA carrier. Gastroenterol 2008;134(4)(Suppl 1):A715-6
23. Lehmann A, Blackshaw LA, Elebring T, et al. The new reflux inibitor AZD3355 has a low propensity for inducing central side effects due to its affinity for the GABA carrier. European Gastroenterology Week, Vienna, Austria, 21 October 2008: abstract OP266
24. McDermott CM, Abrahams TP, Partosoedarso E, et al. Site of action of GABA(B) receptor for vagal motor control of the lower esophageal spincter in ferrets and rats. Gastroenterology 2001;120:1749-1762
25. Boeckxstaens GE, Denison H, Ruth M, et al. Effect of AZD3355, a novel GABAB agonist, on reflux and lower esophageal sphincter function in patients with GERD with symptoms despite proton pump inhibitor treatment. Dig Dis Week Chicago, IL, USA, 1 June 2009;136:abstract M1861
26. Fransson B, Silberg DG, Niazi M, et al. Effect of food on the bioavailability of AZD3355, a novel reflux inhibitor, in healthy subjects. Dig Dis Week, Chicago, IL, USA, 1 June 2009;135:abstract M1911
27. Lal R, Sukbuntherng J, Tai E, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009;330(3):911-921
28. Gerson L, Huff F, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2009. [Epub 29 Dec 2009]
29. Vakil N, Huff J, Bian A, et al. Arbaclofen placarbil monotherapy decreases GERD symptoms in subjects with previous PPI therapy. DDW 2009 Conference, Chicago, IL, USA, 1 June 2009
30. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005;108:294-307
31. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008;103:20-26
32. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007;5:1385-1391
33. Arai K, Takeuchi Y, Watanabe H, et al. Prokinetics influence the pharmacokinetics of rabeprazole. Digestion 2008;78:67-71
34. Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol 2010;45(4):413-421
35. Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs 2008;68:981-991
36. Miwa H, Koseki J, Oshima T, et al. Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa. J Gastroenterol 2009. [Epub 18 Dec 2009]
37. Suzuki H, Inadomi JM, Hibi T. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:688-696